Aldeyra Therapeutics, Inc.

Biotechnology • Healthcare • Lexington, MA, United States • ALDX (NCM)

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

781 761 4904 131 Hartwell Avenue, Lexington, MA 02421, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance

Yahoo Finance • Dec 22

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving Average - Should You Sell? - MarketBeat

MarketBeat • Dec 24

Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan

Stock Titan • Nov 13

Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Stocktwits

Stocktwits • Dec 16

Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛

富途牛牛 • Dec 22

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Aldeyra Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Aldeyra Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Aldeyra Therapeutics, Inc. have?

Aldeyra Therapeutics, Inc. has approximately 8 employees.

What industry is Aldeyra Therapeutics, Inc. in?

Aldeyra Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Aldeyra Therapeutics, Inc. a publicly traded company?

Yes, Aldeyra Therapeutics, Inc. is publicly traded under the ticker symbol ALDX on the NCM. The company has a market capitalization of approximately $0.32 billion.

Where is Aldeyra Therapeutics, Inc. headquartered?

Aldeyra Therapeutics, Inc. is headquartered in Lexington, MA, United States at 131 Hartwell Avenue, Lexington, MA 02421, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.